Rare association of polyneuropathy and Crohn’s disease: a clinicopathological study of 4 cases

Kararizou, Evangelia; Davaki, Panagiota; Speggos, Konstantinos; Stamboulis, Elevtherios

doi:10.5114/pjp.2012.32774

Cited by 7 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figueroa and colleagues just recently reported a 20-year incidence of 0.7% in a population-based study [Figueroa et al 2013]. Most of the IBD-associated neuropathies seem to be nonvasculitic [Kararizou et al 2012].…”

Section: Secondary Systemic Vasculitismentioning

confidence: 99%

Diagnosis and therapeutic options for peripheral vasculitic neuropathy

Blaes

2015

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Vasculitis can affect the peripheral nervous system alone (nonsystemic vasculitic neuropathy) or can be a part of primary or secondary systemic vasculitis. In cases of pre-existing systemic vasculitis, the diagnosis can easily be made, whereas suspected vasculitic neuropathy as initial or only manifestation of vasculitis requires careful clinical, neurophysiological, laboratory and histopathological workout. The typical clinical syndrome is mononeuropathia multiplex or asymmetric neuropathy, but distal-symmetric neuropathy can frequently be seen. Standard treatments include steroids, azathioprine, methotrexate and cyclophosphamide. More recently the B-cell antibody rituximab and intravenous immunoglobulins have shown to be effective in some vasculitic neuropathy types.

show abstract

Section: Secondary Systemic Vasculitismentioning

confidence: 99%

Diagnosis and therapeutic options for peripheral vasculitic neuropathy

Blaes

2015

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…Patients with IBD can also develop a mononeuropathy or multifocal motor neuropathy [11]. The diagnosis of polyneuropathy is based on clinical and electrophysiological studies, but histologic examination of the peripheral nerve biopsy, which reveals axonal degeneration and/or demyelination, may be decisive in establishing the final diagnosis [12]. Peripheral neuropathies have been reported to occur just after the initiation of anti-TNF-a therapy or many years after [13].…”

Section: Methodsmentioning

confidence: 99%

Inflammatory bowel disease and demyelination: more than just a coincidence?

Katsanos

Κατσάνος

2014

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Infliximab and other anti-TNF-α agents have been implicated for drug-induced demyelination in patients with inflammatory bowel diseases (IBDs). We evaluated existing data from MEDLINE and EMBASE and conducted a narrative review to investigate further the aforementioned association. Our literature search highlighted 34 case reports, 3 case-control studies, 1 prospective and 7 retrospective cohort studies published in English. Available data suggest that IBD patients can manifest demyelinating events in both central and peripheral nervous system, however, they are still insufficient to conclude whether anti-TNF-α therapies are an independent risk factor for demyelination. Prospective cohort studies with internal control groups are needed to estimate the true incidence of demyelinating disorders in patients with IBD and to elucidate if anti-TNF-α therapy increases further the risk of demyelination.

show abstract

“…Analysis of the histopathological findings revealed a varying degree of demyelination and axonal degeneration. All patients received immunosuppression with steroids but assessment of the response was not possible [25].…”

Section: Types Of Ibd-associated Peripheral Neuropathiesmentioning

confidence: 99%